[EN] BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE 1,4-DIHYDROPYRIDINE SUBSTITUÉS PAR INDAZOLE BI- ET TRICYCLIQUES ET LEURS UTILISATIONS
申请人:BAYER SCHERING PHARMA AG
公开号:WO2010094405A1
公开(公告)日:2010-08-26
This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.
[EN] FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF<br/>[FR] DÉRIVÉS DE LA 1,4-DIHYDROPYRIDINE À SUBSTITUTION FUROPYRIDINYLE ET LEURS MÉTHODES D'UTILISATION
申请人:BAYER SCHERING PHARMA AG
公开号:WO2011061157A1
公开(公告)日:2011-05-26
This inventionrelates to novel 4-(furo[3,2-c]pyridin-2-yl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.
BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF
申请人:Michels Martin
公开号:US20120035409A1
公开(公告)日:2012-02-09
This invention relates to novel bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.
FUROPYRIDINYL-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND METHODS OF USE THEREOF
申请人:Michels Martin
公开号:US20130131055A1
公开(公告)日:2013-05-23
This invention relates to novel 4-(furo[3,2-c]pyridin-2-yl)-1,4-dihydropyridine derivatives having protein tyrosine kinase inhibitory activity, to a process for the manufacture thereof and to the use thereof for the treatment of c-Met-mediated diseases or c-Met-mediated conditions, particularly cancer and other proliferative disorders.
Improvements in and relating to (3-aryl-5-isothiazolyl)ureas
申请人:ELI LILLY AND COMPANY
公开号:EP0129407A2
公开(公告)日:1984-12-27
Novel (3-aryl-5-isothiazolyl)-ureas, which are useful as aquatic algicides, terrestrial herbicides, and aquatic herbicides, are described herein. These ureas are prepared from the corresponding 5-amino-3-arylisothiazoles with a ureido forming reagent. Further provided are methods of use and formulations comprising these urea products.